exemestane

The drug is used for adjuvant therapy in postmenopausal women with early-stage invasive breast cancer (after 2–3 years of tamoxifen therapy), as well as for the treatment of advanced breast cancer in postmenopausal women if the disease progresses after the use of antiestrogens.

Form: tablets, sugar-coated

ATC: L02BG06

Manufacturer: Pfizer Italia S.r.l.

The drug is prescribed for adjuvant therapy in postmenopausal women with early-stage invasive breast cancer (after 2–3 years of tamoxifen therapy), as well as for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed after the use of antiestrogens.

Form: tablets, film-coated

ATC: L02BG06

Manufacturer: EiGen Pharma Limited (all stages of manufacturing process)

The drug is used for adjuvant therapy in postmenopausal women with early-stage invasive breast cancer (after 2–3 years of tamoxifen therapy), as well as for the treatment of advanced breast cancer in postmenopausal women if the disease has progressed after the use of antiestrogens.

Form: tablets, film-coated

ATC: L02BG06

Manufacturer: Eugia Pharma Specialities Limited

The drug is prescribed to women in postmenopause for adjuvant therapy of early-stage breast cancer (after 2–3 years of tamoxifen therapy), as well as for the treatment of advanced breast cancer if the disease progresses after the use of antiestrogens.

Form: tablets, film-coated

ATC: L02BG06

Manufacturer: Syndan Pharma S.R.L.

The drug is prescribed for adjuvant therapy in postmenopausal women with early-stage invasive breast cancer (after 2–3 years of tamoxifen therapy), as well as for the treatment of advanced breast cancer in postmenopausal women if the disease progresses after the use of antiestrogens.

Form: tablets, film-coated

ATC: L02BG06

Manufacturer: Genepharm S.A.

The drug is indicated for women in the postmenopausal period for adjuvant therapy of early-stage breast cancer (after 2–3 years of tamoxifen therapy), as well as for the treatment of advanced breast cancer if the disease progresses after the use of antiestrogens.

Form: tablets, film-coated

ATC: L02BG06

Manufacturer: Remedica Limited

The drug is prescribed for adjuvant therapy in postmenopausal women with early-stage invasive breast cancer (after 2–3 years of tamoxifen therapy), as well as for the treatment of advanced breast cancer in postmenopausal women whose disease progresses after the use of antiestrogens.

Form: tablets, film-coated

ATC: L02BG06

Manufacturer: Synthon Hispania, S.L. (full production cycle)